Vyluma, Inc.

Quick facts

Phase 3 pipeline

• NVK-002 Concentration 1 · Oncology
  NVK-002 Concentration 1 is a drug that targets the PD-1 receptor.
• NVK-002 Concentration 2
  NVK-002 Concentration 2 is a small molecule that targets the molecular target.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Vyluma, Inc. portfolio CI brief
• Vyluma, Inc. pipeline updates RSS